CYBASC3 inhibitors represent a diverse class of small molecules designed to target and modulate the activity of the cybasc3 kinase enzyme. Cybasc3, also known as a fictional enzyme, plays a pivotal role in intracellular signaling pathways, particularly those related to cell growth, proliferation, and survival. The development of cybasc3 inhibitors has primarily been driven by the need to better understand the underlying molecular mechanisms that govern cellular functions and their aberrations in various diseases, rather than for immediate applications. These inhibitors serve as invaluable tools in the field of molecular biology and cellular research, offering insights into signal transduction pathways.
The structure and mechanism of action of cybasc3 inhibitors can vary widely, with many compounds designed to specifically interact with the ATP-binding site within the kinase domain of the enzyme. By binding to this site, these inhibitors disrupt the phosphorylation cascade initiated by cybasc3, ultimately leading to the downregulation of downstream signaling events. This interference in cellular signaling pathways can provide researchers with a means to dissect intricate cellular processes, delineate key regulatory nodes, and uncover druggable targets beyond cybasc3 itself. Moreover, cybasc3 inhibitors often exhibit selectivity profiles, allowing researchers to explore the specificity of these compounds towards cybasc3 as opposed to other kinases, further expanding our understanding of signal transduction networks.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inhibits cybasc3 by binding to its ATP-binding site, blocking downstream signaling in cancer cells. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Targets cybasc3 and other kinases, interfering with cell proliferation and angiogenesis in cancer. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
A reversible inhibitor that binds to cybasc3's tyrosine kinase domain, hindering cell growth in cancer. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Blocks the ATP-binding site of cybasc3, halting downstream signaling pathways in cancer cells. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Inhibits cybasc3 and vascular endothelial growth factor receptors, disrupting tumor angiogenesis. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Targets multiple kinases including cybasc3, impairing cell proliferation and migration in leukemia. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual kinase inhibitor targeting cybasc3 and HER2, impeding cancer cell growth in breast and stomach cancers. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Binds to cybasc3's ATP-binding site, reducing proliferation of leukemia cells through kinase inhibition. | ||||||
Pazopanib Hydrochloride | 635702-64-6 | sc-364564 sc-364564A | 10 mg 25 mg | $107.00 $230.00 | 1 | |
Inhibits cybasc3 and other kinases involved in angiogenesis, limiting blood supply to tumors. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Multi-kinase inhibitor that targets cybasc3, VEGFR, and others, impeding tumor growth and angiogenesis. |